NEW YORK, Dec. 6, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

World Market for Prescription Arthritis Treatments, The

http://www.reportlinker.com/p0702912/World-Market-for-Prescription-Arthritis-Treatments-The.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Arthritis is one of the most common human ailments worldwide. Arthritis is a complex family of musculoskeletal disorders with many causes that are not fully understood. The most crippling of the arthritis family is rheumatoid arthritis, which is an autoimmune disease. Successful treatment of arthritis has resulted from a growing array of therapies available to physicians.

While these pharmaceutical products are still used regularly, new disease-modifying therapies have produced the most impressive results in treating more severe types of arthritis. Additionally, combination therapies continue to grow in preference and offer exciting results in disease management.

This Kalorama Information report, The World Market for Prescription Arthritis Treatments, details the market for these treatments. The report provides market sizes and forecasts for the following categories of treatments:

• Non-steroidal Anti-inflammatory Drugs (NSAIDs)

• Disease Modifying Anti-Rheumatic Drugs (DMARDs)

• Biologic Response Modifiers (BRMs) and Immunosuppressants

For each category, the report breaks down the regional market (US, Europe, Japan, Rest of World), lists major products, and provides market share among major competitors.

There are several issues and trends that are shaping this market. Some of the topics, discussed in this report include:

• US Economic Impact of Arthritis

• World Economic Impact of Arthritis

• Obesity and Arthritis

• Trends in Insurance and Reimbursement

• Threat to Anti-TNF Dominance

• ADAM-12 Gene Discovery

• New Pricing Structure in Germany

The information and analysis presented in this report are based on extensive interviews with senior management of top companies in the worldwide arthritis treatment market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 20 industry executives and product managers to validate and obtain expert opinion on current and future trends in the worldwide prescription arthritis treatment market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.

CHAPTER ONE: EXECUTIVE SUMMARY

Introduction

Scope and Methodology

Product Market Summary

Issues and Trends Affecting Market

Competitor Analysis

CHAPTER TWO: INTRODUCTION

Overview

Local Joint Disorder Function

Etiology and Pathogenesis

Clinical Manifestations

Osteoarthritis

Etiology and Pathogenesis

Clinical Manifestations

Treatment

Infectious Arthritis

Etiology and Pathogenesis

Clinical Manifestations

Systemic Disorders of Joint Function

Rheumatoid Arthritis

Etiology and Pathogenesis

Clinical Manifestations

Ankylosing Spondylitis

Clinical Manifestations

Psoriatic Arthritis

Clinical Manifestations

Enteropathic Arthritis

Clinical Manifestations

Adult Onset Still Disease

Clinical Manifestations

Juvenile Rheumatoid Arthritis

Clinical Manifestations

Still Disease

Polyarticular Onset

World Demographics

CHAPTER THREE: WORLDWIDE NON-STEROIDAL ANTI-INFLAMMATORY DRUG MARKET

Product Description

Market Forecast and Growth

Markets by Geographical Region

United States

Europe

Japan

Rest of World

Competitive Landscape

CHAPTER FOUR: WORLDWIDE DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TREATMENT MARKETS

Product Descriiption

Sulfasalazine (Azulfidine-Pfizer)

Gold Compounds

Penicillamine (Cuprimine-Merck)

Chloroquine (Aralen-Sanofi-Aventis)

Methotrexate (Trexall-Duramed; Rheumatrex-DAVA Pharmaceuticals)

Leflunomide (Arava-Sanofi-Aventis)

Market Forecast and Growth

Markets by Geographical Region

United States

Europe

Japan

Rest of World

Competitive Landscape

CHAPTER FIVE: WORLDWIDE BIOLOGICAL RESPONSE MODIFIERS AND IMMUNOSUPPRESSIVE DRUG MARKETS

Description

Tumor Necrosis Factor

Glucocorticoids

Azathioprine (Azasan-Salix)

Adalimumab (Humira-Abbott)

Anakinra (Kineret-Amgen)

Basiliximab (Simulect-Novartis)

Daclizumab (Zenapax-Roche)

Etanercept (Enbrel-Amgen)

Infliximab (Remicade-Janssen Biotech)

Rituximab (Rituxan-Biogen Idec)

Abatacept (Orencia-Bristol-Myers Squibb)

Market forecast and Growth

Markets by Geographical Region

United States

Europe

Japan

Rest of World

Competitive Landscape

CHAPTER SIX: WORLDWIDE ARTHRITIS TREATMENT MARKET SUMMARY AND COMPETITIVE ANALYSIS

Market Overview

Product Market Summary

Product Market Analysis by Geographical Region

6 Worldwide Arthritis Treatment Products Competitive Analysis

CHAPTER SEVEN: ARTHRITIS RESEARCH AND DEVELOPMENT TREATMENTS

Overview

Duexis

Gel-One

ACZ

Apremilast

Fostamatinib

Lodotra

Stelara

Tofacitinib

CHAPTER EIGHT: ARTHRITIS TREATMENTS ISSUES AND TRENDS

Overview

US Economic Impact of Arthritis

World Economic Impact of Arthritis

Obesity and Arthritis

Trends in Insurance and Reimbursement

Threat to Anti-TNF Dominance

ADAM- Gene Discovery

New Pricing Structure in Germany

CHAPTER SEVEN: CONCLUSIONS

Conclusion One

Conclusion Two

Conclusion Three

Conclusion Four

Conclusion Five

CHAPTER EIGHT: COMPANY PROFILES

Introduction

Abbott Laboratories

Amgen, Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb

Galapagos NV

Genentech, Inc.

Horizon Pharma

Janssen Biotech, Inc

Novartis International AG

Pfizer, Inc.

Roche

Regeneron

UCB

LIST OF COMPANIES

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Summary Table: Total World Arthritis Treatment Revenue and Growth Rate by Drug Type 2011 ($millions)

Summary Figure:The World Prescription Arthritis Treatments Market Share Summary 2011

CHAPTER TWO: INTRODUCTION

Table 2-1: Total Global Population by Selected Geographical Region, 2000 - 2050

Table 2-2 World Prevalence of Rheumatoid Arthritis by Region

Figure 2-1:: World Prevalence of Rheumatoid Arthritis, Percent by Region

CHAPTER THREE: WORLDWIDE NON-STEROIDAL ANTI-INFLAMMATORY DRUG MARKET

Table 3-1: Select Marketed Non-steroidal Anti-inflammatory Drugs

Table 3-2 Market Size and Growth for NSAIDs in the Global Arthritis Treatment Market 2009-2016 ($millions)

Figure 3-1 Market Size and Growth for NSAIDs in the Global Arthritis Treatment Market 2009-2016 ($millions)

Table 3-3: The Worldwide Market for NSAIDs by Geographical Region (US, Europe, ROW) 2009-2016

Figure 3-2: The Worldwide Market for NSAIDs Products by Region (US, Europe, Japan, ROW), 2011

Figure 3-3: The Worldwide Market for NSAIDs Products by Region (US, Europe, Japan, ROW), 2016

Table 3-4: The Worldwide NSAIDs Product Market Share by Supplier 2011

Figure 3-4: The Worldwide NSAIDs Product Market Share by Supplier 2011

CHAPTER FOUR: WORLDWIDE DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TREATMENT MARKETS

Table 4-1: Selected Prescription Disease Modifying Anti-Rheumatic Drugs

Table 4-2: Market Size and Growth for DMARDs in the Global Arthritis Treatment Market 2009-2016 ($millions)

Figure 4-1: Market Size and Growth for NSAIDs in the Global Arthritis Treatment Market 2009-2016 ($millions)

CHAPTER FIVE: WORLDWIDE BIOLOGICAL RESPONSE MODIFIERS AND IMMUNOSUPPRESSIVE DRUG MARKETS

Table 5-1: Selected Prescription Immunosuppressant and Other Biologic Drugs

Table 5-2 Market Size and Growth for BMRs and Immunosuppressants in the Global Arthritis Treatment Market 2009-2016 ($millions)

Figure 5-1 Market Size and Growth for BRMs and Immunosuppressants in the Global Arthritis Treatment Market 2009-2016 ($millions)

Table 5-3: The Worldwide Market for BRMs by Geographical Region (US, Europe, Japan, ROW) 2009-2016

Figure 5-2: The Worldwide Market for BRM Products by Region (US, Europe, Japan, ROW), 2011

Figure 5-3: The Worldwide Market for BRM Products by Region (US, Europe, Japan, ROW), 2016

Table 5-4: The World Biologic Response Modifiers Arthritis Treatment nd Market Share by Supplier 2011

Figure 5-4: The Worldwide BRMs and Immunosuppressives Product Market Share by Supplier 2011

CHAPTER SIX: WORLDWIDE ARTHRITIS TREATMENT MARKET SUMMARY AND COMPETITIVE ANALYSIS

Table 6-1: Total World Prescription Arthritis Treatment Revenue and Growth Rate by Drug Type 2011

Figure 6-1: The World Prescription Arthritis Treatments Market Share Summary 2011

Table 6-3: The World Market for Prescription Arthritis Treatments, by Geographic Region, 2011

Figure 6-2: The World Market for Prescription Rheumatoid Arthritis, by Geographic Region, 2011

To order this report:

Pathology Industry: World Market for Prescription Arthritis Treatments, The

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Back to top

RELATED LINKS
http://www.reportlinker.com